Skip to content
★ Sign in to follow
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. logo

Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. Stock: price and insider trades · China

华兰股份

CN·Mcap CN¥9.7BHealth Care

No insider purchase over the last 90 days. The latest, by 华一敏, was filed 17 Apr 2026.

Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.: what insiders have been doing

Every trade that managers of Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. 2 insiders have disclosed 2 filings since 4 November 2025.

On the market, 1 insider bought (1 purchase totalling €948) while 1 insider sold (1 sale totalling €139k). The net balance comes to €138k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 board member among the declarants. One trade stands out by size: a sale of €139k from 刘雪, disclosed on 14 October 2026.

Compared with its exchange (521 companies, median 2 filings), a count of 2 filings is typical. The full history, which starts in 2026, counts 1 purchase against 1 sale.

The most recent open-market purchase was published on 17 April 2026, 205 days ago.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€948
1 ops. · all time
Sell Volume
€138,833
1 ops. · all time

Who traded when

BuySale
刘雪1 sale
华一敏1 buy

Since the insiders bought

  • Filed 17 Apr 2026 · 205 days ago · €948
    +1.4%
    Entry CN¥80.93 · Close at T+90 CN¥82.04

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 15,347 of 26,912 companies
47.4
score / 100
Value
36
Quality
59
FCF yld-0.2%
Earn yld0.6%
EV/EBITDA·
ROE1.0%
Gross mgn39%
Net mgn9.7%
Debt/EBITDA0.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥45.62
Analyst consensus
1 analysts
·
CN¥68.05Target CN¥68.05(+49%)CN¥68.05
Income statement
RevenueCN¥619.5M
Gross profitCN¥240.8M39% margin
EBITDACN¥138.3M22% margin
Net incomeCN¥60.2M4.0% margin
Valuation
PER (trailing)253.4x
P/Book4.5x
Beta1.05
Balance sheet & cash
Market capCN¥9.7B
Total debtCN¥90.7M
Free Cash Flow-CN¥17.1M
Debt / Equity6%
Profitability & ownership
ROE1.0%
ROA0.3%
% insiders36.4%
% institutions18.6%
Last declaration on 14 October 2026
Declarations2 total
  • ▼
    董事,副总经理,董事会秘书Executives
    1M CNY32SZSE
    19,000 shares@ CN¥410.8319100.0% of flowA股XSHESZSE:273000001704542300
  • ▲
    董事,高管Executives
    7,620 CNY15SZSE
    100 shares100.0% of flowA股XSHESZSE:273000000453895780
    Canonical exit: 16 Jul 2026 (T+90)

2 of 2 declarations

About Jiangsu Hualan New Pharmaceutical Material Co.,Ltd.

华兰股份 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of biological and pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations